Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma

NCT03086174 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Kidney Cancer Stage Iv
Advanced Melanoma

Interventions

BIOLOGICAL: humanized anti-PD-1 monoclonal antibody Toripalimab

Sponsor

Shanghai Junshi Bioscience Co., Ltd.